These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27869361)

  • 1. Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy.
    Kim H; Park W; Huh SJ; Choi DH; Noh JM; Im YH; Ahn JS; Park YH; Nam SJ; Kim SW; Lee JE; Cho EY
    Asia Pac J Clin Oncol; 2017 Aug; 13(4):329-336. PubMed ID: 27869361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer.
    Gülben K; Berberoğlu U; Kinaş V; Başkan E
    Acta Chir Belg; 2014; 114(3):153-9. PubMed ID: 25102703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
    Haque W; Verma V; Hatch S; Suzanne Klimberg V; Brian Butler E; Teh BS
    Breast Cancer Res Treat; 2018 Aug; 170(3):559-567. PubMed ID: 29693228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).
    Shim SJ; Park W; Huh SJ; Choi DH; Shin KH; Lee NK; Suh CO; Keum KC; Kim YB; Ahn SD; Kim SS; Ha SW; Chie EK; Kim K; Shin HS; Kim JH; Lee HS
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):65-72. PubMed ID: 24161425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients.
    Goorts B; van Nijnatten TJ; de Munck L; Moossdorff M; Heuts EM; de Boer M; Lobbes MB; Smidt ML
    Breast Cancer Res Treat; 2017 May; 163(1):83-91. PubMed ID: 28205044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locoregional Recurrence and Survival Outcomes in Breast Cancer Treated With Modern Neoadjuvant Chemotherapy: A Contemporary Population-based Analysis.
    Murchison S; Nichol A; Speers C; Gondara L; Levasseur N; Lohrisch C; Vallieres I; Truong P
    Clin Breast Cancer; 2022 Oct; 22(7):e773-e787. PubMed ID: 35915021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
    Spring L; Greenup R; Niemierko A; Schapira L; Haddad S; Jimenez R; Coopey S; Taghian A; Hughes KS; Isakoff SJ; Ellisen LW; Smith BL; Specht M; Moy B; Bardia A
    J Natl Compr Canc Netw; 2017 Oct; 15(10):1216-1223. PubMed ID: 28982747
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prognostic value of sequencing of radiotherapy and chemotherapy following breast-conserving surgery for patients with breast cancer].
    Zhong QZ; Wang Z; Tang Y; Rong QL; Wang SL; Jin J; Wang WH; Liu YP; Song YW; Fang H; Chen B; Qi SN; Li N; Tang Y; Zhang JH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):308-314. PubMed ID: 28550675
    [No Abstract]   [Full Text] [Related]  

  • 12. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
    White R; Dinneen T; Makris A
    Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
    Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
    [No Abstract]   [Full Text] [Related]  

  • 16. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
    J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
    Yang Y; Im SA; Keam B; Lee KH; Kim TY; Suh KJ; Ryu HS; Moon HG; Han SW; Oh DY; Han W; Kim TY; Park IA; Noh DY
    BMC Cancer; 2016 Jul; 16():515. PubMed ID: 27444430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
    Loibl S; Jackisch C; Lederer B; Untch M; Paepke S; Kümmel S; Schneeweiss A; Huober J; Hilfrich J; Hanusch C; Gerber B; Eidtmann H; Denkert C; Costa SD; Blohmer JU; Nekljudova V; Mehta K; von Minckwitz G
    Breast Cancer Res Treat; 2015 Jul; 152(2):377-87. PubMed ID: 26109347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Sagara Y; Takada M; Ohi Y; Ohtani S; Kurozumi S; Inoue K; Kosaka Y; Hattori M; Yamashita T; Takao S; Sato N; Iwata H; Kurosumi M; Toi M
    Breast Cancer Res Treat; 2018 Oct; 171(3):675-683. PubMed ID: 29971625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.